Biohaven reports second quarter 2022 financial results and reports recent business developments

Antitrust approvals have been granted by the relevant governing authorities, including the federal trade commission ("ftc"), with respect to the previously announced pfizer inc. acquisition of biohaven pharmaceutical holding company ltd.; preliminary proxy statement has been filed with the sec nurtec® odt (rimegepant) trx volumes grew 11% and net product revenue was $194 million, up sequentially 57% anticipated closing of the merger agreement necessitates accounting of derivative losses in the amount of $1.57 per share resulting in a total second quarter reported net loss of $6.21 per share; non-gaap adjusted net loss1 for the second quarter was $3.82 per share featured 31 new and encore presentations, including three late-breakers and three oral presentations, spotlighting robust nurtec odt and zavegepant migraine data at the 64th annual scientific meeting of the american headache society; oral presentations included first of its kind study in migraine reporting on the safety and benefits of nurtec odt when used as preventive treatment and as-needed for acute treatment of migraine zavegepant nasal spray new drug application ("nda") filing accepted by the u.s. food and drug administration ("fda"), with a prescription drug user fee act goal date set for first quarter of 2023 commenced enrollment in phase 3 clinical trial assessing efficacy and safety of taldefgrobep alfa in patients with spinal muscular atrophy new haven, conn.
BHVN Ratings Summary
BHVN Quant Ranking